ReviewPublished 9 October 2026Prostate cancer: advancements in targeted therapiesIlesha Ewart · Manreet RandhawaFrontiers in Endocrinologydoi 10.3389/fendo.2026.1924299
ReviewPublished 27 August 2026Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry, and adaptive radiopharmaceutical therapyMallareddy Banala · Shabbir Ezuddin · Mark Foley · Russ KukerFrontiers in Nuclear Medicinedoi 10.3389/fnume.2026.1935247
ReviewPublished 31 July 2026Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoringChimbabantu Kaoma · Mike Sathekge · Joseph Chalwe · Kgomotso Mokoala · Mankgopo KgatleFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1852641
ReviewPublished 15 July 2026PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencingNatalia Gierulska · Nina Jankowska · Adrianna Kwiatkowska · Piotr Kuchno · Kinga Łysak · Katarzyna Szklener · Kamil Kośmider · Magdalena SkórzewskaOncology Reviewsdoi 10.3389/or.2026.1834484
Mini ReviewPublished 22 April 2026Progress in the application of 68Ga-Pentixafor PET/CT in lung cancer: a reviewLisheng Liu · Juxing ZhangOncology Reviewsdoi 10.3389/or.2026.1797818
Mini ReviewPublished 5 December 2025Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumorsXiaolong Wu · Yu Wang · Yingchun Li · Wenli HuFrontiers in Nuclear Medicinedoi 10.3389/fnume.2025.1737443
